



Ziopharm
ONCOLOGY

Nov. 12, 2018

Forward-Looking Statements

This presentation contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the progress, timing and results of preclinical and clinical trials involving the Company's drug candidates, and the progress of the Company's research and development programs. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include, but are not limited to: whether chimeric antigen receptor T cell (CAR⁺ T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of our other therapeutic candidates will advance further in the preclinical or clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether chimeric antigen receptor T cell (CAR⁺ T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, and our other therapeutic products will be successfully marketed if approved; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the quarter and fiscal year ended December 31, 2017, and subsequent reports that the Company may file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

Financing Provides Balance Sheet Security, Runway into 2Q2020

Prior to October 5, 2018 Announcement

- \$31.7 million cash on hand at Ziopharm
- Additional \$29.6 million prepaid available at MD Anderson
- \$157.3 million in preferred stock held by Intrexon, 12% interest
- 51.9 million common shares if converted on Sept. 30, 2018

Upon Closing of Private Placement

- \$80 million cash on hand at Ziopharm*
- Additional \$29.6 million prepaid available at MD Anderson
- Preferred stock agreement eliminated; no dilution

Updated Financials after Private Placement

Condensed Consolidated Balance Sheet

Cash, cash equivalents and short term investments as of Nov. 13, 2018	\$80 M
At MD Anderson Cancer Center from prepayment for programs to be conducted by the Company as of Sept. 30, 2018	\$29.6M

Current plans and resources will be sufficient to fund planned operations into the second quarter of 2020 and pre-payments to MD Anderson fund planned programs there into 2020



Ziopharm
ONCOLOGY

